Current Report Filing (8-k)
January 16 2020 - 5:15PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 16,
2020 (January 12, 2020)
_______________________
Seneca Biopharma,
Inc.
(Exact name of registrant as specified in Charter)
Delaware
|
|
001-33672
|
|
52-2007292
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File No.)
|
|
(IRS Employee Identification No.)
|
20271 Goldenrod Lane, 2 nd Floor, Germantown, Maryland
20876
(Address of Principal Executive Offices)
(301) 366-4960
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. [ ]
Securities registered pursuant to Section 12(b) of the Act:
Title of Class
|
|
Trading Symbol
|
|
Name of Each Exchange on Which Registered
|
Common stock, par value $0.01 per share
|
|
SNCA
|
|
NASDAQ Capital Market
|
|
Item 7.01
|
Regulation FD Disclosure.
|
During the week of January 12, 2020, representatives of Seneca Biopharma,
Inc. (“Company”) presented at both the Sachs Associates 3rd Annual Neuroscience Innovation Forum and the
Biotech Showcase, both of which were held in San Francisco, California. The representatives are also conducting one-on-one meetings
with potential joint venture and strategic partners. Filed herewith as Exhibit 99.01 are the slides that were presented at such
conferences. The slides are also available on the Company’s website at www.senecabio.com.
The information contained in this Current Report on Form 8-K and
the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such
information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in or
exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report that is required
to be disclosed solely to satisfy the requirements of Regulation FD.
|
Item 9.01
|
Financial Statement
and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
|
January 16, 2020
|
Seneca Biopharma, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Kenneth Carter
|
|
|
|
By: Kenneth Carter
|
|
|
|
Executive Chairman
|
|
|
|
|
|
INDEX OF EXHIBITS
Seneca Biopharma (NASDAQ:SNCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seneca Biopharma (NASDAQ:SNCA)
Historical Stock Chart
From Apr 2023 to Apr 2024